top of page

BackTable / Urology / Podcast / Episode #256

The Role of ctDNA in Bladder Cancer Diagnosis & Treatment

with Dr. Alberto Pieretti

Could ctDNA testing allow us to treat bladder cancer earlier, smarter, and more effectively? In this episode of BackTable Urology, Dr. Alberto Pieretti, a urologic oncologist at Cleveland Clinic Weston Hospital, joins host Dr. Jose Silva to explore the emerging role of ctDNA in bladder cancer management.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

The Role of ctDNA in Bladder Cancer Diagnosis & Treatment with Dr. Alberto Pieretti on the BackTable Urology Podcast
Ep 256 The Role of ctDNA in Bladder Cancer Diagnosis & Treatment with Dr. Alberto Pieretti
00:00 / 01:04

BackTable, LLC (Producer). (2025, August 22). Ep. 256 – The Role of ctDNA in Bladder Cancer Diagnosis & Treatment [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Alberto Pieretti discusses The Role of ctDNA in Bladder Cancer Diagnosis & Treatment on the BackTable 256 Podcast

Dr. Alberto Pieretti

Dr. Alberto Pieretti is a urologic oncologist at Cleveland Clinic Weston Hospital in Parkland, Florida.

Dr. Jose Silva discusses The Role of ctDNA in Bladder Cancer Diagnosis & Treatment on the BackTable 256 Podcast

Dr. Jose Silva

Dr. Jose Silva is a board certified urologist practicing in Central Florida.

Synopsis

Dr. Pieretti and Dr. Silva discuss how ctDNA can refine staging, identify patients at risk of recurrence, and guide decisions on when to intensify treatment. The conversation also examines its potential to detect actionable mutations, inform precision therapies, and shape the design of future clinical trials in urologic oncology.

Timestamps

0:00 - Introduction
2:50 - Overview of Bladder Cancer
12:59 - Overview of ctDNA
20:34 - Current ctDNA Trials
27:21 - Clinical Implications of ctDNA
31:20 - Conclusion

Resources

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma - PubMed
https://pubmed.ncbi.nlm.nih.gov/37500339/

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | New England Journal of Medicine
https://www.nejm.org/doi/abs/10.1056/NEJMoa2408154

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

BCG Shortage: Salvaging Bladder Cancer Care When Standard Care Is Scarce with Dr. Amy Luckenbaugh on the BackTable Urology Podcast
Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

bottom of page